I-MAB SPONS.ADS/1 -0001 (F:0VY) — Market Cap & Net Worth
Market Cap & Net Worth: I-MAB SPONS.ADS/1 -0001 (0VY)
I-MAB SPONS.ADS/1 -0001 (F:0VY) has a market capitalization of $189.29 Million (€161.91 Million) as of September 20, 2026. Listed on the F stock exchange, this Germany-based company holds position #16850 globally and #1587 in its home market, demonstrating a -7.28% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying I-MAB SPONS.ADS/1 -0001's stock price €1.40 by its total outstanding shares 115648505 (115.65 Million). Also see 0VY current and non-current assets for a full breakdown of the balance sheet.
I-MAB SPONS.ADS/1 -0001 Market Cap History: 2020 to 2026
I-MAB SPONS.ADS/1 -0001's market capitalization history from 2020 to 2026. Data shows change from $4.46 Billion to $189.29 Million (-27.88% CAGR). Also see cash flow conversion of I-MAB SPONS.ADS/1 -0001 for how efficiently the company converts equity into cash flow.
I-MAB SPONS.ADS/1 -0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how I-MAB SPONS.ADS/1 -0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check I-MAB SPONS.ADS/1 -0001 stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
352.99x
I-MAB SPONS.ADS/1 -0001's market cap is 352.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $5.44 Billion | $13.81 Million | -$365.78 Million | 393.58x | N/A |
| 2022 | $451.59 Million | $-1.55 Million | -$371.05 Million | -291.16x | N/A |
| 2023 | $223.09 Million | $632.00K | -$207.73 Million | 352.99x | N/A |
Competitor Companies of 0VY by Market Capitalization
Companies near I-MAB SPONS.ADS/1 -0001 in the global market cap rankings as of September 20, 2026. Review 0VY tangible net assets ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to I-MAB SPONS.ADS/1 -0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
I-MAB SPONS.ADS/1 -0001 Historical Marketcap From 2020 to 2026
Between 2020 and today, I-MAB SPONS.ADS/1 -0001's market cap moved from $4.46 Billion to $ 189.29 Million, with a yearly change of -27.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €189.29 Million | -58.08% |
| 2025 | €451.59 Million | +300.00% |
| 2024 | €112.90 Million | -49.39% |
| 2023 | €223.09 Million | -50.60% |
| 2022 | €451.59 Million | -91.69% |
| 2021 | €5.44 Billion | +21.82% |
| 2020 | €4.46 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of I-MAB SPONS.ADS/1 -0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $189.29 Million USD |
| MoneyControl | $189.29 Million USD |
| MarketWatch | $189.29 Million USD |
| marketcap.company | $189.29 Million USD |
| Reuters | $189.29 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About I-MAB SPONS.ADS/1 -0001
NovaBridge Biosciences, a biotechnology company, focuses on the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. It is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; VIS-101, a bispecific antibody, which … Read more